DNA - NYSE

Good evening. I'm Joseph Fridman, Director of Communications and Corporate Affairs here at Ginkgo, where it's my fifth year. During that time, I've had the pleasure and the privilege of working with our Investor Relations team. usually behind the scenes of these earnings calls. And so it's exciting to be supporting you today in this more front-facing role. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO. Thanks, as always, for joining us. We're really looking forward to updating you on our progress today. As a reminder, during the presentation today, we will be making forward-looking statements. These involve risks and uncertainties. And -- so please refer to our filings with the SEC to learn more about these risks and uncertainties, including in our most recent 10-K. . Today, in addition to updating you on the quarter and the full year results, we're going to provide updates on our path towards adjusted EBITDA breakeven as well as customer progress in our cell engineering business across both our services and tools offerings and the latest offerings in our biosecurity business. As usual, we'll end with a Q&A session, and I'll take questions from analysts, investors and the public. You can submit questions for that to us in advance via X, please tank your post with the #GinkgoResults or e-mail us or in boxes [email protected]. I'll be checking that throughout the call. All right. Over to you, Jason.

Thanks, Joseph, and thanks, everyone, for joining us. We always start with our mission of making biology easier to engineer. And similar to last quarter, our focus for that mission is on these 3 key objectives. First, we want to reach adjusted EBITDA breakeven while maintaining a cash margin of safety. And we ended this quarter with $562 million in cash and no bank debt and significantly exceeded our original cost-cutting target for 2024. And -- you're going to see this reflected in a dramatically reduced level of cash burn in Q4 versus Q3. And I'm really happy to see this. A cash margin of safety is what protects can go from having to raise capital in conditions that aren't favorable, and we want to keep our cash war chest large while reducing cash spending and expanding our sources of revenue. This is a simple strategy, right? Like just drive the cost down and keep expanding, and we executed on it really well in the second half of 2024, and we will keep pushing on it in 2025. That is not changing. Second, while we cut costs, we need to keep serving our current customers and adding new customers. Q4 saw us achieve a record number of technical milestones in a single quarter, showing our team's ability to continue to deliver great new science for our customers. I'm really proud of that delivery across the team. Finally, we want to grow our cell engineering revenue and continue to expand our tools offerings, which I'm going to talk a lot more about in the strategic section. Okay. I'm excited to get into all of that. But first, I want to hand it over to Mark to discuss the financial results for the quarter.

Thanks, Jason. I'll start with the Cell Engineering business. Cell Engineering revenue was $35 million in the fourth quarter of 2024, up 29% compared to the fourth quarter of 2023. This increase was primarily driven by growth with large biopharma customers and government accounts. partially offset by declines with smaller customers in the industrial biotech segments. As we've discussed previously, this customer mix shift has been a headwind to growth in prior quarters. And so we're very pleased to now see the positive impact of the shift in this quarter's revenue. On a full year basis, Cell Engineering services revenue was $174 million in 2024. And -- as a reminder, in the third quarter of 2024, Ginkgo recognized $45 million in noncash revenue from a release of deferred revenue relating to the mutual termination of a customer agreement we had with Motif FoodWorks, one of our platform ventures. Excluding this impact, cell engineering revenue was $129 million in 2024, down 10% compared to the full year of 2023. We -- this decrease was driven by the customer mix shift discussed previously, along with commercial changes related to the restructuring. In the fourth quarter of 2024, we supported a total of 138 active programs across 85 customers on the Cell Engineering platform. This represents a 5% increase in active programs year-over-year. As we discussed in our previous 2024 earnings calls, the nature of programs that we take on with our customers has evolved significantly following our adjustments to commercial terms and the launch of our tools offerings. As such, going forward, we are no longer going to report a new program metric. However, we are going to provide additional perspective on active programs in the quarter, which I will discuss in a moment. Before I do that, I will close out 2024 by noting that we added a total of 31 new programs and contracts in Q4 of 2024, of which 14 were generally comparable in size and scope to historically reported new programs and were included in the current active program count on the prior slide. In addition, we commenced 17 other customer contracts in the quarter that represent a variety of small deal architypes. These are generally much smaller in scope and shorter in duration. We are very pleased that we've been able to continue the momentum with our biopharma customer base, including 5 new large pharma logos and 7 new data points contracts. Now going forward, we're going to provide you with a revenue-generating active program count metric that we think will be more useful to analysts that are using this to model revenue. This metric will include all programs that generated revenue in the quarter, including smaller programs that I refer to as other contracts on this slide. Further, in this metric, we will only include programs that were revenue generating in the quarter. So for example, at any point in time, we have a significant number of programs that are either just starting or are wrapping up. And so they aren't generating any meaningful revenue. We'll exclude those for you, which will give you a better indication of revenue per program in the quarter, and you can measure how that trends over time in a more meaningful way. In the appendix, we've provided you with a preliminary look at this new metric for the past 4 quarters as a reference, and we welcome your feedback. Now turning to Biosecurity. Our Biosecurity business generated $9 million of revenue in the fourth quarter of 2024 at a gross margin of 17%. Revenue and gross margin were down quarter-over-quarter, and as you'll note, lumpy during the course of the year due partly to the timing of signing of a customer contract in Q2 of this year. On a full year basis, Biosecurity revenue for 2024 was $53 million, down 51% from $108 million in 2023. As a reminder, our K-12 COVID testing contracts ended in the third quarter of 2023 and -- and the business has now moved entirely towards building out both domestic and international infrastructure for Biosecurity. And now I'll provide more commentary on key items for the rest of the P&L. We've changed the presentation of this slide this quarter to align with our segment reporting disclosures. We believe this will give you more insight into the underlying profitability of our 2 segments. And specifically, we'll give you more information on the cost structure and how that is changing as we undertake our restructuring. A full reconciliation between segment operating loss, adjusted EBITDA and -- and GAAP net loss can be found in the appendix. Segment operating expenses. So starting with the more significant items in segment OpEx. In the fourth quarter of 2024 Cell Engineering, R&D expense decreased 31% from $73 million in the fourth quarter of 2023 to $50 million in the fourth quarter of 2024. And -- Cell Engineering G&A expense decreased 49% from $40 million in the fourth quarter of 2023 to $21 million in the fourth quarter of 2024. These decreases were driven by our restructuring efforts. On a full year basis, Cell Engineering R&D expense decreased from $336 million in 2023 to $272 million in 2024. And -- G&A expense decreased from $171 million in 2023 to $115 million in 2024. Net loss. So it is important to note that our net loss includes a number of noncash income and/or expenses as detailed more fully in our financial statements. Because of these noncash and other nonrecurring items, we believe adjusted EBITDA is a more indicative measure of our profitability. And as noted, we are now showing you adjusted EBITDA at the segment level so that you can more clearly see the relative profitability of Cell Engineering and Biosecurity. The significant improvement in Cell Engineering segment operating loss in the fourth quarter of 2024 compared to the comparable prior year period was due to the previously discussed drivers of improved revenue and reduced operating expenses. Moving further down the page, you'll note that total company adjusted EBITDA in the fourth quarter was negative $57 million, which was up from negative $101 million in the fourth quarter of 2023. The principal differences between segment operating loss and total company adjusted EBITDA, and -- in the fourth quarter relates to the carrying cost of excess leased space, which you can see was $9 million in Q4 and $26 million in the year. This cost represents the base rent and other charges relating to lease space, which we are not occupying net of sublease income. We will continue to break that out for you going forward since that is a cash operating cost that is not related to driving revenue right now and can be potentially mitigated through subleasing. On a full year basis, total Ginkgo adjusted EBITDA was negative $293 million, which was up from negative $365 million in 2023. This improvement in adjusted EBITDA can be attributed to the fact or the impact of the previously mentioned third quarter noncash deferred revenue release as well as the restructuring implemented over the last 3 quarters. And finally, I'll just make one additional comment relating to cash burn in the quarter. Cash burn in the fourth quarter of 2024 was $55 million, down significantly from $114 million in the third quarter of 2024. We -- this significant decrease in cash burn sequentially was a result of the restructuring and it was further impacted positively by higher revenue, which was partly driven by the successful completion of a number of technical milestones in the quarter, as mentioned by Jason. We would further expect to reduce the cash burn run rate significantly from this level by the fourth quarter of 2025, and -- though we expect some lumpiness in the progression during the year due to timing of working capital and onetime payments. Jason will discuss our increased target for OpEx reductions later in the presentation. As we did last year, we'd also like to provide you with some updated data points relating to downstream value share. On the left-hand side of the chart, you can see that as of the end of 2024 we have the potential to earn up to $1.7 billion in milestone payments based on customer collaborations previously entered into, with the majority of those payments dependent on successful commercialization of a product. This figure does not include potential royalties. So on the right side of the page, we are showing you the full total of programs for which we currently have downstream value share potential, including those with royalties. While it is harder to estimate the total potential value on royalty deals, you'll see the volume of programs there remain substantial. You'll also see that the decrease in potential milestone payments was approximately $700 million when comparing 2024 to 2023. A -- we do expect reduction in milestones if a program doesn't meet a technical goal or a customer changes commercial direction. Previously, we made up for these decreases with new milestone-bearing programs. But as a result of the commercial changes we implemented in Q2 and our focus on tools offerings that generate near-term revenue, we did not book a significant amount of new potential milestones in the year. Now I'd like to provide some commentary on our outlook for the full year 2025. Before I get into the Cell Engineering revenue numbers, there are 2 important points of context. Firstly, I want to reiterate that our primary objective is to reduce cash burn. We like Ginkgo's competitive position and are very encouraged by what we're seeing with our tools offerings. However, we are still selling into a challenging biotech R&D market and are being diligent with respect to new business that we take on. Secondly, the government segment has been a source of growth for us in the past year and our momentum there has been very strong. However, given current uncertainties in this area, we are baking that risk into the low end of our guidance. That said then, our Cell Engineering revenue guidance is a range of $110 million to $130 million. We believe we are taking a conservative approach in providing this guidance range. We could see potential upside to this range coming from our new tools offerings where we have a solid BD pipeline and as discussed earlier, closed a number of new biopharma deals in Q4. Our Biosecurity revenue guidance for 2025 is at least $50 million. As we have in the past, we are guiding to our approximate current level of contracted backlog for the year, including an expected midyear program renewal and have a pipeline of opportunities we are pursuing beyond that. Also to clarify, this business is almost entirely dependent on government funding, which is a risk we have been managing since we started operations in the Biosecurity space. And so we are providing guidance here under the assumption that our government contracts continue. And finally, we expect total revenue for the year 2025 to be in a range of $160 million to $180 million. In conclusion, we're pleased with our overall execution of the restructuring thus far as evidenced by the reduction in cash burn in Q4. And -- we are very encouraged by the early traction we are seeing in tools. However, we also acknowledge that we continue to operate in a very uncertain macro environment. We believe we are taking a prudent approach to managing both with our risks and growth opportunities along a path to adjusted EBITDA breakeven by the end of 2026 and maintaining a cash margin of safety. And one final footnote. On the financial reporting front, I can confirm that we remediated our SOX material weakness and wanted to express my appreciation to the team for all the work that went into addressing that. So back over to you, Jason.

Thanks, Mark. Similar to the last 2 quarters, I'm going to use the first strategic section to focus on Ginkgo's efforts to reduce costs and update you on our restructuring efforts. Next, I'll cover our expansion into life science tools and services. This is a big change we made last summer. We now have some data on how it's going. We're seeing a market trend in the biopharma industry towards needing more data for AI models where customers haven't been well served by traditional life science tools companies and CROs. And I think there's a nice opening for Ginkgo there. Finally, I'll share more details on the specific tools and service offerings in Ginkgo data points and Ginkgo automation, where we've been getting good traction with customers over the last 6 months. . Okay. Let's get started. All right. So when we announced our restructuring less than a year ago, we set a $100 million spending cut target for 2024 with an additional $100 million reduction set for 2025. In our Q3 call last November, we reiterated those targets, having achieved a considerably accelerated site consolidation and cost takeout. Today, we've achieved $190 million annualized run rate reduction through Q4 when compared to Q1, and -- and that's partially offset by a headwind where we have increased rent charges related to the Bio Fab 1 facility. And you can see that reflected in our quarterly cash burn in Q4 2024 being reduced down to $55 million. As I said, having a cash margin of safety is very important to me as that is how you avoid having to take on a dilutive fundraising when you don't want to and so I'm absolutely thrilled to see the progress on our cash burn here while still having over 600 -- or $560 million in cash and cash equivalents with no bank debt at the end of Q4. We -- Among our peers, pursuing advanced technology and AI and biotech, we're in a really strong position, and we plan to keep it that way. I want to thank the Ginkgo team for the incredibly hard work in 2024, while undergoing a lot of change to get us to where we are today. There's still a lot of work to do in '25, but I do really like our position from here. You can see also our progress reflected between Q1 and Q4 of 2024. We really like this chart comparing total revenue to cash expenses, and that's inclusive of the cost of sales. My goal in 2025, like I said, is keep this trend going. As Mark mentioned, we are being conservative with our revenue guidance in '25, given uncertainty around government R&D funding, obviously, a lot of changes there. But we've already taken steps to further drop our cash expenses, and I'm hopeful we'll do even better than the $60 million annual improvement that we have as our target shown there. Honestly, this is getting easier as we see what is working and not working throughout the business based on the changes we made last summer. We can move very quickly, at Ginkgo. We showed that in 2024, and we're on an even more solid footing now. So the rate that we can make changes should only improve in the following year. I'm also really proud of the team for their quick work in spinning down and moving out of those various sites you see on this map, in particular, their work on the Lesaffre acquisition of Altar, ensure that we retain critical access to technologies, and overall, the operational team's ability to maintain customer delivery while moving equipment and people has been really impressive. So we were in too many sites. Those were stakes that we made over the past couple of years and being able to in the face of drawbacks and biotech move out of those quickly and consolidate around what was working, again, has been really impressive. I will say, please don't hesitate to reach out if you are growing biotech, looking for space in Cambridge or Boston. I am the friendliest biotech landlord here. We've been making headway on subleases, but we still have a lot of lab space available that we'd love to get you into. I want to note as well that despite our site consolidation, we still maintain technical and programmatic teaming and corporate entities in Europe that are at work and delivering on our European contracts, including a very exciting new one that I'll mention later today, the RANGER program. Okay. All right. So let's move on to the next topic. All right. So I mentioned Ginkgo has been expanding outside of sort of our original solutions business into tools and services. So I want to give a little more color on that for where we're headed in 2025. So the first bit here, as you can see, our historic solutions activities, we are really selling to sort of the head of R&D of a large biopharma, right? So this was a deal -- kind of like the deals you would see negotiated at JPMorgan, they took a long time to close. They were large programs, multiyear big checks, and they included downstream value in the form of milestones or royalties. The big change in 2024 was in addition, we're still doing those solutions deals, we started selling tools. And for tools, the customer could -- is sort of not the head of R&D, but someone that reports to that reports to the head of R&D or made reports to the person that reports to the head of R&D. And this is really -- if you look on this chart that I quite like, at the high end, we have sort of a lot of customization and technical risk taken on by a biotech company. So an extreme form of this would be a small biotech in Cambridge developing a unique drug and hoping it to license it to a large biopharma partner. So that's sort of asset licensing model is at the high end of technical risk, the high end of customization. You also get a lot of value for that, right? You can get bought out for -- you see these billion, multibillion-dollar deals for preclinical or at least clinically proven drug assets that are pre-commercial. As you go down that curve a bit, you got to our solutions business at Ginkgo. These are highly customized, right? We knew these deals with Novo Nordisk and Merck and Pfizer and so on to support drug discovery or manufacturing, R&D. We are getting large milestones and royalties and Mark shared sort of the aggregate numbers there, more than $1.7 billion of milestones and then a whole bunch of more royalties on top of that. However, again, highly customized, and we are taking on some technical risk. We -- we met more technical milestones than ever in the last quarter, but sometimes we don't meet them. And then that hurts us on the revenue side. And certainly, we're dependent on customers to commercialize to see the really big value in the downstream. And so that's great. I'll talk about -- talking about a second. It just takes a while to get to. That dotted line in the middle sort of represents where you go to the point where you're not customizing as much, you're not taking technical risk and you lose that reach through into the customers' revenues on their products. But you get what amounts to a more easily scalable business. And so we're going to talk about data points, which is our business that's most akin to like a traditional CRO, contract research organization, generating large data assets for customers to order for -- often for AI model training. I'm not going to talk about as much today, but we've released AI models up on the web that folks should try out. And then finally, the other business where we're seeing a lot of traction is we're an equipment business. We're selling our automation platform here at Ginkgo, and that has been going really, really well. So again, on the left-hand side, we've got larger but longer term potential upside where we get a piece of a customer's product, and we get to show every technology at Ginkgo rolled up to do that R&D project for a customer, and on the right-hand side, it's really the customer science is driving, we get near-term fee revenue, faster sales cycle and a much wider swath of customer. So I think these are very complementary. Us having the solutions business is really helping us sell tools. But they are very different. And so it was a risk jumping into this last year. And so I'm really happy to see that, that has paid off so well for us. And the reason it has is that we're seeing customer interest in large data assets to enable AI models in the biotech industry. And if you go around and talk to heads of R&D or even the CEOs of pharma companies, you're going to hear that AI is sort of 1 and 2 on their priority list, both internally to drive efficiency in the organization. Also to help them develop new products. And this has really led kicked off by -- there's a partnership between Genentech and Recursion a few years ago that sort of demonstrated the applicability of this, in particular, in the area of target discovery, which I'll talk about later in data points. But I think this kind of owes a little bit of a kick in the butt for the industry, and you saw a lot more people getting interested in this. And as the AI models have improved from the tech industry, it's only driving more of that. So I want to frame like what does this mean for the life science tools industry. So I think on the left-hand side, you can see, and this is a slide I showed a couple of quarters ago as well, the traditional life science tools market, right? It sort of brings a scientist at the bench it is maximally flexible. So that scientist has a hypothesis about an experiment, they want to run to answer a question that they have based on reading a lot of literature and previous results that they've seen in their work, and they want to run that perfect experiment, right? And that perfect experiment, they want to run it tomorrow. So they need all these reagents to be able to show up on very short notice, and they need to have a bunch of equipment and assets available to them right on site and they want it to be exactly the experiment they want. So these huge catalogs from the big tools providers with thousands and thousands of SKUs so that, that scientists can do exactly what they want. By the way, I think this is a really important thing, right? I think we've developed all of our drugs, biotech and biological learnings have come from this tools infrastructure. It's just different than the infrastructure you need if you want to generate data for AI model training. And if you want to generate data for AI model training, what you really care about is the cost per data point generated, because these models get a lot better if they see a lot more data. And so in that case, you don't want infinite flexibility, what you want is sort of infinite scale with less flexibility. In fact, you want a lot of the experiments to be done similarly so that the data can be compared well. And so I think this sort of classic research approach versus what we're calling a data foundry research approach. Again, I think they're very complementary. I don't think we're going to stop doing hypothesis-driven discovery-based science, but I think you're going to have a complement to it where we really need at all the major biopharma companies, all the major bio research institutes out there. You need the ability to generate large sets of data in order to train models and approach it with this AI-based approach. So, I think you're going to see a lot of energy in this direction. We think we're extremely well positioned for this at Ginkgo, but that is the underlying driver that's made adoption of our tools products go so well in the second half of last year. Okay. So now I want to talk a bit more about the specific the 2 products where we've seen the most traction, which is our data points product and our automation product. So if you go to data points here. The very first thing I'll point out is this is a different business model than we have in our solutions. So when customers are seeing our data points offering, they own all the intellectual property. There is no royalties. There's no milestones. We're really generating large data assets on a fee-for-service basis for those customers. There's going to be 2 data points products that are already launched, the Functional Genomics and Antibody Developability. So I'll talk about functional genomics. First, this is really exciting. So this is pretty similar in spirit to what I mentioned with that Genentech Recursion partnership where you're really using AI models to do target discovery, to find new targets to develop drugs against in disease models. And often a customer will have for example, a cell type that they may be developed in-house that's relevant to their disease or maybe they want to take a standard one that's used out in the academic literature and they want to perturb that cell type. And what I mean by perturb is they want to either hit it with a chemical library, so think 10,000 or 30,000 chemicals that they might have in a compound library or they want to perturb it genetically. In other words, they want to make CRISPR knockout of 1,000, maybe 1,000, maybe 10,000 genes in that post cell. And each time you knock out 1 gene or hit it with a compound, you would like that cell to be in a well. And then you would like to read out a high complexity measurement on the performance of that cell. And we have a few different types of measurements we can do, but the most popular so far has been transcriptomics. And so we are able to give you a readout of the transcriptomic profile, but we can also do high imagery, both cell painting and Brightfield on that cell to give you back those sort of many thousands of cells with these high content outputs. We've done this now in 100 different human cell types that we've worked with at Ginkgo, but you can see the ones that have already been onboarded for that high content transcriptomics drug seek on the left there, that we've been doing for customers, skeletal myoblasts, normal skin fibroblasts, HeLa cells, CAR-T cells, so on and so forth. And we don't really have an issue bringing cells on that. We've got a really good hit rate doing that. So again, we're happy to work with customer cells or cells that we have here at Ginkgo.

We then hit 4 different cell types with 6 different concentrations of these drugs and 4 replicates of that, again, in 384-well plates, and then we do a transcriptomic readout of that. We put all that data online. It's about 200 gig per cell type across those cells. And so download it. You can hit that QR code, download and play around with it. And that's been a really good way to bring in new customers for that product. It shows people exactly what they're going to get. The next product I'll talk about in data points is our Antibody Devailability product. Here are the ideas you can send us 100, you can say it's 1,000 antibody sequences. We'll synthesize, express those antibodies and then run a battery of developability assays on them. And so you can see a list here, but these are things like thermostability and heparin binding and polyspecificity.

And to give you a sense of sort of timing and what programs look like. These are just 2 example projects. The first would be an oncology target ID project where you could see the types of cells that we would go after there. And this is 2,000 compounds in 5 different cell lines, that's a 10- to 11-week project, then you get that data right back. The next one over would be for an Alzheimer's target ID here interested in a genetic pergabation. So doing those CRISPR knockouts in this case of 1,000 genes across 3 cell types, and that's a 9- to 10-week return on that data asset. You can see on the right-hand side, the illustration of the different types of data formats that come back to you. So again, really excited about this. The only thing I will mention, coming out next will be RNA data services, and we also recently released an AI models. So you can see the types of design tools that you can generate by using these types of data assets. But again, this is something that will be coming up, and we encourage folks that are working in the RNA, AI space or RNA drug discovery, if they're interested to give us a call, it will be exactly the same as the other 2 offerings in terms of IP rights and no royalties fee for service. So, if you're looking for large data sets and RNA, also give us a call in addition to the sort of Functional Genomics and antibodies. Okay. So that's what I want to say on data points, and we move on next to Ginkgo Automation. I came -- I was in, I guess, near the end of January in San Diego for the Society of Lab Automation and screening/conference. And it was really exciting to be there because there's actually a ton of interest in our reconfigurable automation cards, our rack technology. You might remember, this came in through an acquisition of

Great. Thanks so much, Jason. As usual, for the Q&A, we'll start with a question from the public. I'll remind the analysts on the line that if you'd like to ask a question, please raise your hand on

Yes, happy to take that. Yes, this is actually a key strength at Ginkgo, just given our experience in the solutions business. We've engage with kind of folks all around the R&D stack in these companies. So the short answer is it varies depending on what we're selling. So a solutions deal itself, Basically, our ideal customer persona there is the head of R&D, if it's a large biotech, biopharma like a Novo Nordisk or a Merck. And if it's a small biotech, it's the CEO because we are doing basically an outsourced research project. We're almost like an outsourced R&D team for that R&D leader. If we're selling data points, it's going to, if it's a drug company, really a lead for a drug program. And so that means there's a lot more of those than heads of R&D. So that's exciting to me. It gives us kind of a wider set of folks to engage with, but they're still sort of like 1 or 2 levels below that head of R&D. And then finally, if it's automation, it's the kind of folks that are at that SLAS meeting. It's really the kind of automation leads in these companies who are usually responsible for building out a new work cell or integrated automation setup. That's what I think that's going to change over time. Like knocking I'm sort of optimistic that the racks are such an innovation in the industry that we could ultimately see it just requiring the addition of a new cart to an automation core to bring online a whole new workflow. And so then you might hear from just someone on the technical team who wants to automate something and they give us a call to add that piece of equipment to their existing core. But for today, when we're doing these first sales, it's really sort of the heads of automation at these various large and midsized companies.

Thanks so much. Jason, I've opened up your line from Morgan Stanley.

This is Jason on for Tejas. So I guess starting off maybe just a question on the 2025 guide., What are your assumptions in the 2025 guide for some of the new offerings Ginkgo has launched, namely tools, data points and Ginkgo Automation. Are you anticipating a material contribution from any of these offerings in 2025?

Do you want to take that, Mark?

So I'd be happy to take that. So we are, I think, being relatively conservative in the guide with respect to the new offerings. For context, in 2024, your sort of baseline is single-digit millions of contribution from that. And so in the guide, I think we're anticipating at least getting into double-digit millions in terms of revenue contribution. And so what you should maybe think of is there are certainly upside opportunity from the tools offerings, but that within the guide, we're being relatively conservative there.

Yes. And the only thing I'll add to that is, we're coming from basically a standing start on that in mid-'24. It's gotten well enough that you're seeing me direct more of our kind of sales and commercial effort in that direction. So we'll see. I mean the I think is real wind in the sales for data points, especially in the near term and automation on a slightly longer term. So knock on wood again, but we are trying to be conservative given it's a new business.

Got it. That was helpful. And then maybe just if I could ask a follow-up question. Just so you reiterate expectations to reach adjusted EBITDA breakeven by year-end 2026. Where does Ginkgo need to finish in 2025 from an EBITDA perspective for us to feel comfortable about reaching this target? And then could you provide some color on some of your assumptions that you have embedded regarding achieving the target. So any assumptions regarding the range of revenue you need to achieve? Is the success of either tools or data points or can go automation criteria to use this target? And is the OpEx run rate once the current restructuring initiatives completed sufficient? Or do you need on additional levers on the OpEx front?

Yes. So I'd be happy to take that one. So I think a good way to frame it is to look at where we finished in Q4 of 2024. So that was adjusted EBITDA of negative $57 million. So we talked -- so the levers that we have are really revenue costs and then sublease. So on the cost front, we talked about increasing the cost takeout run rate by another $60 million by the end of this year. And so on a sort of quarterly basis, Jason, you would see at least a $15 million contribution to adjusted EBITDA just from that alone. And I'll say, largely speaking, the actions that get us that $60 million have already been taken or are in motion. We will also continue to push on the cost lever. So we're not saying we're sort of done there. And so through 2025 and 2026, we think there would be additional opportunities on the cost front. So that's part of the equation to get into adjusted EBITDA breakeven by the end of '26. Then you've got sort of revenue growth, of course, would be -- we would expect to be a contributor. And then you've got sublease sort of mitigating the $65 million on an annual run rate basis of excess space cost. Now on an annual basis, about $8 million of that just naturally expires in 2026. The rest of that, we would have to deal with through sublease income. It's a challenging market and so we're not banking necessarily on being able to do that. But that's another sort of piece of the equation. And then I guess the only sort of final point, Jason, would be that downstream value share in 2026 is a real opportunity. There's a fairly significant amount of -- of the programs that we have that would be in play in 2026. Again, we're not necessarily banking on that to us to adjusted EBITDA breakeven, but that would be another opportunity that would be in play for 2026. So yes, so hopefully, that sort of frames it for you.

Yes. My only addition to that, Jason, is the I think if you look at biotech market today, right, it's generally like a tough market, you're having a lot of time, less investment in R&D and so on and so forth. And we are -- we have launched these new products, which again, I'm happy they're going well, but they are new for us. So you see us being conservative on revenue guide because from my standpoint, costs are under our control, right? So as we march to breakeven, I'm going to be looking at that, right? If we're doing better on revenue grade. If we're not, we'll take out costs. It's not that's the equation that's not more complicated than that. And I do think we have plenty of levers.

Awesome.

Evie from Goldman.

Filling in for Matt tonight. How should we think about the margin profile differences between the traditional foundry data points and automation? I understand it's early days and revenue is limited at this point, but just trying to get a sense for where growth will help push you towards EBITDA breakeven?

Yes. So on the data points businesses for the tools offerings, we are really targeting the way we think about margins is we really target what you would see in kind of a solid sort of CRO services market of 40% plus gross margins. I will just say the business is still not even close to being out of scale where you can really understand sort of what's possible in terms of gross margin. We do think our offering there is pretty differentiated. We also think we have a way to sort of scale into growth in a cost-effective way. So that's generally how we're targeting it. On the -- compared to the traditional solutions offerings, you'll remember that we were using to some extent, downstream value share there as part of the thesis in terms of getting to margins. And so -- and so we were willing to do business at a sort of much lower kind of gross margin profile. And that, of course, has evolved, we're no longer sort of willing to do that, and you see that kind of in the cost structure coming down. And so -- but that's how we're thinking about the tools business, Evie.

Okay. That's super helpful. And then what are you seeing in your sales funnel now that you've opened up your sales process towards more tools. Are you seeing the volume pickup you sort of expected through the less customized, less risky offerings?

Yes. This is something I was super excited about. I mean I think Mark mentioned it, but we had 8 -- or sorry, 7 new data points deals in the last quarter. We had 5 new logos to Ginkgo, right? Like that -- what we found with the data points -- in fact, I had a customer here today, who was like, "Oh, yes, I talked to you all 1 year ago, 1.5 years ago, and we kind of left saying like, wow, we can't really get behind like the royalties and milestones for this kind of a project. . And so I assume you listened to us, and that's why you've updated your business model, right? It sounds great to me. So we have this these new interactions, even with places we've talked to before now, we're like they're basically introducing us to procurement now, and we're treated much more like a straightforward kind of CRO interaction, it's way faster to close. And then what we're finding with data points is we can do kind of a smaller proof of concept, people want to try it out. Like I encourage customers listening on the call. You can do a relatively small project, 100,000 here, 200,000 there to generate a data set and see how it works in your area in your cell type and so on. And if it looks good, you can generate a much larger data set, specifically for model fine-tuning or other ML. And so that -- again, it feels pretty good. It feels very different than when we were selling solutions. It's certainly been like wind in my commercial sales. So yes. Automation is a different crew. Like I would say that is really -- it is more of a sales cycle where you're going through, they're planning to do a build out. At least for our first installs, you'll see us go in with kind of like a traditional automation sales cycle into like a work cell type build. However, I think, again, what's unique about the racks, and we aren't even seeing this with companies like Ogden, you can just add to them in small batches after that, right? So if we can just get in places, I think then we'll have a much quicker sales cycle than its traditional and integrated automation.

Mark from BTIG.

Great. Can you hear me? Yes, again. Excellent. So I know the new administration has been in office, not terribly long here, but I'm just curious, in your Biosecurity guidance, you assumed no change to any government contracts. Obviously, there could be some changes, right? So help us to just better understand who these contracts are, which agencies they're with. And give us a sense, maybe just remind us if you think there are synergies remaining between your Biosecurity business and your core Cell Engineering business.

Yes. I can give a few comments there. So we do have government contracts both on the Cell Engineering side and the Biosecurity, as you're mentioning. The Cell Engineering contracts are much more like traditional R&D contracts, again, places like DARPA and ARPA and so on. . And there, I think you have seen with this administration coming in and making changes, certainly, the research universities are being impacted pretty quickly by changes to how they're approaching research funding. I will say like -- and this is part of the reason why we also were conservative on the guide for this year. We don't want to -- like we don't want to count on things. We'll see what happens. I will say, I think we're in the era with this administration. Certainly, my interactions in D.C., where the new leads have not -- they're either just getting in or aren't even yet in for a lot of these agencies. And certainly, their deputies are not in place yet. And so all you're seeing in advance of that is cutting. What I think is going to be interesting about this administration is once those leads are in, I think you're going to have some people that do have certain vision for things, it's going to be potentially different than the visions of people that have come before, and they're going to want to move on it just as aggressively and quickly as you've seen them move on the cuts. And that represents an opportunity. I'd say less of an opportunity on the research side. I think research will just be research. I do think research money will keep flowing there, it's maybe just a question project by project. But on the Biosecurity side, that could really go just in wildly different directions, depending on what the administration's plans are. Obviously, we've gotten out of the WHO has big impact on CDC in 1 of our contracts with CDC. Where do they go with all that, right? Are they going to have an alternative to WHO some of the programs we have, these are even programs outside the U.S. like -- we do, like we've mentioned before, monitoring in airports in Africa and in the Middle East and so on. Those could be real assets for some of the things that previously were being relied on just voluntary reporting from countries in the WHO. We could now maybe monitor those with hard technology. And I think that's something that could appeal to this administration. But it's early days because we don't really have the leadership in place yet in some of those.

Okay. Great. And by the way, you've done a nice job on the cash burn reduction. Clearly, you've made a lot of changes to the company in the last several quarters. . But Mark, you talked about how you'll no longer report a new program metric. Maybe just remind us what we should be looking for. Obviously, we can track your Cell Engineering revenue. But remind us how we can sort of -- what other ways can we track the health of your funnel and your business going forward?

Yes. So what you'll get is, I would say, an enhanced version of the current active program metric. And if you look at the appendix of the presentation, you'll get a preliminary view for the last 4 quarters of what that metric looks like, and we'd be happy to talk about it with you offline further and get your feedback on that. But you'll get sort of an enhanced current active program metric that will give you a better sense of what the real revenue per program at Ginkgo is. Because as I mentioned on the call, the number -- the metric you get right now includes a lot of programs that are either starting or stopping and therefore, aren't contributing revenue. And so when you try to take revenue divided by that program count and do the -- I know the analytics that you all do, you're not really getting a sense of what revenue per program is. So this will give you a better sense of that. And because you'll have 4 quarters of history, you'll be able to see how that's trending over time. And that's what I would use to model revenue. But we can talk about that in a little bit more detail off-line.

And I appreciate the comment on that, and I get -- I'll give a shout out to the team for an enormous amount of work to get that cash burn down in Q4. It's -- and it's top of mind and a lot of what you see, I showed that slide there where we get the revenue up, bring the cost down and they line up and there we go. And I like Ginkgo's position, as I mentioned, in terms of from a technology basis, the things we've accumulated, the talent we have here, if you look across the industry, it's tough times in general. And I think if we can get to that point where we are even close to breakeven in the near term, that allows us to be sort of like a port in that storm. And so I do think that's a really important thing, and that's why we're putting so much effort into the cost takeouts.

Brendan from TD.

All right. Maybe just piggybacking on some of the AI commentary. I actually wanted to ask how you're thinking about growth trajectory of some of these newer offerings? I understand all understand it's early days here. But just from a high-level strategy perspective, should we anticipate any shift in priority and maybe timing for kind of expanding these newer products, just given all the headlines in recent months? . And then I guess, honestly, related to that, just wondering if you see any potential synergies with your biosecurity offerings there moving forward? .

Yes. So I think I mentioned this a bit in the talk, but the interest in AI from the -- it's really the mid and large kind of biopharma, biotech companies. is what's driving all the interest in data points and even like on a second order basis, a chunk of interest in the automation. So I do think that will keep going, right? Like it's not going away. And I think you're seeing the success of the models just in driving efficiency across things like clinical filings and all this stuff, making it very obvious to leadership that it would be nice to see similar gains in their research outputs. And so I think that's what -- that's kind of driving it. I think then like I mentioned, you quickly run into this realization that even at these large biopharma companies, the existing data sets you have across the many hundreds of drug development programs you would have done over the years were all done in like slightly different ways with different controls and different data standards and then also they were done at the lab bench. And so very smart science was done, but maybe not huge data assets were generated. And so everyone, I think what's kind of originally hoping, I'll just go mine all this data we already have. And surely, that will let me train these models. And then the realization has set in that actually you mostly need to generate new data. And so that, I would say that, like, hey, we're interested. Oh, we've done the 9-month cycle to look at our existing data and realize we want to make new stuff or either new just relevant to our new drug programs has kind of clicked through, and that's why you're seeing new demand. So I do think that will keep going. When it comes to Biosecurity, I think -- yes, I mean one of the things -- look, I cannot emphasize how or we are as sort of a species and establishing Biosecurity so far. But you could absolutely imagine a future world where you have basically rapid at site DNA sequencing that sequencing is getting sent up into the cloud, and it's being analyzed across thousands of collection sites by AI models that are basically looking for things that look bad. And this is roughly the analogy would be like what you see with cybersecurity, right? Places like Microsoft and others who are monitoring across many, many end points. see an anomaly they're like, "Oh, that's a new virus. And then are you able to -- try to contain it and then also push patches and update. We got to get to this place when it comes to virus. It's just literally crazy. And so I do think that type of infrastructure getting that in place is absolutely going to evolve. AI analysis of just the raw amount of genomic data. But first step is start collecting the genomic data. And that's really what we've been putting in place to begin with. So I think there's a little bit of like I think the data collection is probably the driver initially for this stuff in both cases.

Yes. Matt from William Blair.

A couple of times.

Do you want to start the question again?

Yes, sure, do you have me? Yes. So a couple of times you've referenced an effort to be conservative with guidance. And obviously, at Challenge, the last couple of years was in these very long sales cycles given the complexity of deal that you're targeting, and you have a lot of work to simplify that and really work with customers to reduce sales cycle kind of meet them where they're at. . Can you just help us, when you say more conservative -- does that just reflect shorter sales cycles, so more data around close time? What is kind of the early data points around the tools and data points offering in terms of close time? How do you really arrive at confidence it conservative guidance.

So yes, I'll start by saying, Matt, on the solutions side, remember, we do programs that, in many cases, are multiyear programs. So we're coming into 2025 with a pretty substantial backlog of business. that we need to burn. And this is on the sort of commercial side of the company with lots of like good customers and long-standing customers. So there's sort of a base of business that is already baked in. When we say conservative, we're really talking about some uncertainty around the government side of solutions, government has been a source of growth for us when you just look at the numbers in 2024. And was expected to be a source of further growth in 2025. And just given sort of the current environment, very specifically, we thought we should be conservative on that piece of solutions. And then finally, on tools, like I said...

Maybe in '24, that was, what, 15%, 20% or something. .

Yes, of revenue. So you can look at the -- you'll see it in the 10-K, the percent of revenue by -- by industry segment, but government was sort of roughly speaking, about $20 million of revenue for us in Solutions in 2024, and we would have expected that to grow in 2025. So -- so that's really, Matt, what we mean by conservative. And then on the tool side, I think just -- you heard me say it in 1 of the earlier questions, but we -- starting from a base of effectively 0 have sort of modeled in the guidance, getting into kind of double-digit millions of revenue but not beyond that. We do see potential just based on pipeline to do better than that in the year, but that's not in the guidance on the tool side.

Okay. And then, Jason, the division of building a company that can accelerate and make R&D more efficient maybe it looks a little different today with data points and with tools, but that's still really where you're headed. And I would think that over time, there could be a number of customers that might work with can't go in a number of different ways, both on the automation side, maybe it's data points projects and then larger enterprise efforts. Do you have any of those examples yet? Is that something over time you think you can get to? And what's kind of the path for here to there? .

Yes. There is sort of like an interesting like flyer -- so yes, Ginkgo's mission is make biology easier to engineer, data points and tools very clearly fit into that. It's infrastructure we built. We can go to market with it quickly. We can sell it in a new way. All that, again, was a hypothesis last summer that has now been proven true. So I'm really excited about that. It takes something like robotics, right? I mean that robotics infrastructure, obviously is relevant to biotech research, but it's really connecting laboratory equipment into an integrated setup. You could for other types of laboratory work as well. Certainly, we expect demand and have already seen demand in our funnel from things like diagnostics companies and things like that. I think you'll absolutely see that as a base of customers for us in automation. But you're also seeing some efforts from like the large tech companies like I was on a panel with R&D for Microsoft. And like they're doing like AI for science. Google, who is a strong partner of ours. They just came out with a pilot for scientists, which is actually pretty amazing. And so I think you are seeing the Frontier AI Lab say what these reasoning models at the high end, one of the use cases could be changing how we do scientific and engineering discovery in the world. And if you want to do that, then those models need to interact with the real world. They need to be able to run experiments. And so again, I feel like automation could be a really big part of that. That's not a big part of my revenue plans in '25, although we do have some -- we have contracts data generation with major tech company. But the -- but it is a thing to watch. And if that becomes an actual big area of investment among the major tech players you can expect Ginkgo to be right there. So for example, we'll have our racks at the big NVIDIA event. So if you want -- if you're happy to go to that, you can check them out in person there. Yes.

There, Matt. Jason, from Morgan Stanley. If you have any other questions, happy to take a second one, but if not I'll close with a retail question. So a retail question, this comes from Caballos. The question is, is Ginkgo revenue impacted at all by avian flu, potential pandemics, et cetera, a matter of personal concern. So I appreciate you guys answering that.

So I think -- I mean, like H5N1, here's what I'll say about Biosecurity. It's -- we have been building out the infrastructure, obviously, to support persistent pervasive surveillance in between certainly pandemics, but even in between various regional outbreaks like there's some formal thing that came out like DRC, I just saw today, right? So you're going to have these -- you're going to have regional stuff that creates spot demand and then the occasional larger, more global thing. H5N1 has pandemic potential like entostory, right? So it's just one of these things you have to watch at the human transmission level. And if it does, you should absolutely again, expect us to be right there like we were during COVID to just lean right into that and grow. But then there is an interesting angle around -- I mean, like egg prices are up, right? There's a reason for that. And so I do think there's also an angle there potentially with biosecurity just around preserving food security and food pricing, which I think is something that's of interest to this administration and just everyday folks. And so I think that's another angle for biosecurity in the future, but obviously, we pay the most attention to the human stuff.

Thanks so much. Thanks, everybody, for joining us.